Global Drug Delivery Challenges Explained

Two men, Nick A. (left) and Nigel (right), sit at a white table, engaging in a lively and friendly conversation. Both wear checkered shirts and lavalier microphones, suggesting a filmed discussion or interview. Nick holds tissue samples in one hand and gestures animatedly, while Nigel smiles in response. Each has a white mug labeled with their name and a purple star logo. The background is a bright white, creating a clean and professional studio setting.
Resources

Global Drug Delivery Challenges Explained

Topic: Bio Break
YouTube video thumbnail

In this episode of Bio Break, Nick Allan and Nigel Syrotuck dive into the surprising realities of global drug delivery. While medical devices often dominate development conversations, the way drugs are delivered across regions can dramatically change how treatments succeed — or fail.

Nigel reflects on a trip to Italy where food sparked thoughts about oral drug delivery. In regions like Italy, pills and tablets are the most common approach. Larger countries also tend to prefer simple, scalable methods such as pills or injections. By contrast, smaller regions may be more open to specialized treatments that require more time or unique handling.

Regional Differences in Drug Delivery

Drug delivery methods are influenced not just by culture, but also by economics, insurance systems, and infrastructure. For example, biosimilars are more readily accepted in some countries depending on reimbursement structures. Meanwhile, large-scale programs — such as vaccine rollouts — highlight how fragile supply chains can be.

Cold Chain and Pandemic Lessons

Certain drugs, including attenuated vaccines, require strict cold chain maintenance. In developing regions, this presents a major challenge. The COVID-19 pandemic underscored this issue when millions of doses expired due to distribution and storage limitations. As Nick and Nigel note, a drug designed for one part of the world may face barriers to adoption in another, depending on the delivery method.

Indirect ELISA explained with antibody model showing enzyme linked immunoassay detection

Nick and Nigel walk through how indirect ELISA works, why it uses two antibodies instead of one, and when this approach makes the most sense in real diagnostic workflows.

Smartwatch displaying heart rate and ECG-style waveform, illustrating the difference between wellness devices and medical devices in digital health regulation

Ariana Wilson and Mark Drlik break down medical vs wellness devices and explain why two products with identical hardware can fall into completely different regulatory categories.

Nick from StarFish Medical demonstrating antigen detection using a toy antibody model to explain how monoclonal antibodies bind antigens in ELISA diagnostics

Nick and Nigel break down the ELISA assay explained in simple, practical terms using everyday models.

Magnifying glass revealing cracks with the text “This gets missed,” illustrating hidden risks in medical device validation and real-world use.

Ariana Wilson sits down with Mark Drlik to unpack why reprocessing is often one of the hardest challenges engineers face during development.